Our Technology
Therapeutic development often faces challenges associated with poor bioavailability leading to low accumulation in target tissues. One of the most common causes of this phenomenon is clearance by organs, specifically the liver and spleen, which are dedicated to the removal of compounds from the blood. The rapid clearance by these organs decreases therapeutic accumulation in target tissue and can lead to high off-target toxicity in the liver.
Curadigm has approached this challenge from a unique perspective and designed a biocompatible nanoparticle, called a Nanoprimer, which is given just before the therapeutic to reduce its clearance, improve blood bioavailability and decrease liver toxicity. The Nanoprimer accomplishes this through its ability to accumulates rapidly in the liver, following intravenous administration, and transiently & specifically occupy the cells involved in therapeutic clearance. This temporary decrease in clearance improves the therapeutics’ blood bioavailability and accumulation in target tissue while avoiding the hepatotoxicity that can occur from rapid accumulation within the liver. The Nanoprimer is then cleared and therapeutic clearance resumes.